Article info

Original research
Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways

Authors

  1. Correspondence to Professor Thomas Dörner; thomas.doerner{at}charite.de
View Full Text

Citation

Dörner T, Tanaka Y, Petri MA, et al
Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways

Publication history

  • Received June 17, 2020
  • Revision received August 17, 2020
  • Accepted September 12, 2020
  • First published October 9, 2020.
Online issue publication 
January 04, 2021
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.